Thank you.
Just briefly, the decision as to why this appeal wasn't sought is quite well laid out in the regulatory impact analysis statement. That's the statement that traditionally accompanies the regulatory amendments.
In June 2022, when the Governor in Council repealed the amendments, the RIAS contained a nice explanation about why the decision was made at the time to not pursue the litigation. I direct people to that, but the high-level explanation is that, as is stated in the RIAS, the decision about the evolving pharmaceutical landscape was a policy decision that the Minister of Health made, certainly informed, as set out, by the court decisions. However, I think the Governor in Council's rationale for the repeal was focused on that evolving landscape, which, again, was really set out quite well in the RIAS, which I won't take you through.